Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 779 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram Positive Bacterial Infection Clear all
Completed Phase 1Phase 2 Interventional

Pneumococcal Adult-dose Ranging Immunization Study

NCT00169234
View directory record Official record
Conditions
Pneumonia
Interventions
PCV7, Prevnar®, Pneumovax 23
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
70 Years to 79 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Not applicable Interventional Results available

Antimicrobial Stewardship Through MRSA Diagnosis in Emergency Department (ED) Patients With Abscesses

NCT01523899
View directory record Official record
Conditions
Cutaneous Abscess
Interventions
Xpert MRSA/SA SSTI, Standard culture
Device · Diagnostic Test
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 27, 2026, 12:53 PM EDT
Withdrawn Not applicable Interventional

Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)

NCT01842347
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal microbiota
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 2 Interventional

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

NCT00442832
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
TD-1792, Vancomycin
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT04865536
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Not applicable Interventional

Effect of Interleukin-2 on HIV Treatment Interruption

NCT00015704
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

NCT03170609
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
Multivalent group B streptococcus vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Stockbridge, Georgia • Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

NCT00777257
View directory record Official record
Conditions
Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions
T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 17 Years
Enrollment
1,345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
20
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

NCT01273922
View directory record Official record
Conditions
Staphylococcal Infections, Candidiasis
Interventions
NDV-3 investigational vaccine
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The ICON Study: Outcomes After FMT for Patients With IBD and CDI

NCT03106844
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment

NCT00997139
View directory record Official record
Conditions
Nasal Carriers of Staphylococcus Aureus
Interventions
Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 27, 2026, 12:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of Mycobacterial Infections

NCT00018044
View directory record Official record
Conditions
Mycobacterium Infections
Interventions
Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Ciprofloxacin in Humans

NCT00964561
View directory record Official record
Conditions
Anthrax
Interventions
Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug · Other
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

NCT07284654
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
31 valent pneumococcal conjugate vaccine, PCV20, PCV21
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,049 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 27, 2026, 12:53 PM EDT
Completed No phase listed Observational

Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes

NCT00446355
View directory record Official record
Conditions
Clostridium Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2009 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Not applicable Interventional

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000638
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td

NCT00601835
View directory record Official record
Conditions
Diphtheria, Tetanus
Interventions
Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 60 Years
Enrollment
3,651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
2
States / cities
Oakland, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

NCT01048697
View directory record Official record
Conditions
Obesity, Tuberculosis
Interventions
Ethambutol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 2 Interventional

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

NCT02092935
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SMT19969, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Mobile, Alabama • Laguna Hills, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 27, 2026, 12:53 PM EDT
Completed No phase listed Observational

FQ Restriction for the Prevention of CDI

NCT03848689
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
Interventions
fluoroquinolone preprescription authorization, Control
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
5,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 27, 2026, 12:53 PM EDT
Recruiting Phase 4 Interventional

Hypertonic Saline for MAC

NCT04921943
View directory record Official record
Conditions
Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Interventions
Hypertonic saline, Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 1 Interventional

Anthrax Vaccine Clinical Trials

NCT00114621
View directory record Official record
Conditions
Anthrax
Interventions
Anthrax Vaccine, Blood Chemistry, Hematology, Urinalysis
Drug · Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

NCT01929226
View directory record Official record
Conditions
Inhalational Anthrax
Interventions
ETI-204, Placebo
Biological · Other
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 27, 2026, 12:53 PM EDT